Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Luminespib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Jul 2019 Trial has been completed in Norway, according to European Clinical Trials Database record.
- 23 Jan 2017 Status changed from completed to discontinued.
- 16 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.